# An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

> **NCT02294461** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 395 (actual)

## Conditions studied

- Progressive Metastatic Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02294461
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-23
- **Primary completion:** 2015-09-20
- **Final completion:** 2024-07-17
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02294461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02294461, "An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02294461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*